Shots:

• Baxter and BioMerieux enter into an agreement to develop biomarkers for identification & treatment for acute kidney injury (AKI)
• The focus of the agreement is to utilize BioMerieux’s expertise in diagnostics & advancing Baxter’s critical care portfolio including nutrition- renal- hospital and surgical products
•  Additionally- On April 24- 2018 BioMerieux has acquired Astute Medical to develop biomarkers- IGFBP-7- and TIMP-2 for the early risk assessment of acute kidney injuries

Ref: Baxter | Image: The Pharma Letter